Menu

MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

More Info

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

More Info

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

Latest
news

25/09/2018
MorphoSys Announces its Licensee Janssen has Initiated a Phase 3 Trial (...
Read Media Release
17/09/2018
MorphoSys and LEO Pharma Expand Strategic Alliance to Develop Peptide-...
Read Media Release
13/09/2018
MorphoSys and Galapagos Announce Start of a Phase 1 Subcutaneous Bridging...
Read Media Release
13/09/2018
MorphoSys Announces That its Licensee Janssen has Reported That Tremfya(R...
Read Media Release
12/09/2018
MorphoSys and Galapagos Announce U.S. Antitrust Clearance for Global...
Read Media Release
06/09/2018
MorphoSys AG to be listed in MDAX
Read Media Release
08/08/2018
MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202
Read Media Release
01/08/2018
MorphoSys AG Reports Second Quarter 2018 Financial Results
Read Media Release
24/07/2018
MorphoSys Announces Appointment of Jennifer Herron as President of...
Read Media Release
19/07/2018
MorphoSys and Galapagos Sign Global License Agreement for MOR106 with...
Read Media Release

September 25, 2018
Berenberg and Goldman Sachs Seventh German Corporate Conference
Munich, Germany

See conference

 

 

 

 

Simon Moroney, CEO
on Strategy and Goals